Table 2.
Comparison of the prevalence of metabolic syndrome components and chronic kidney disease markers according to thyroid function status
| Variables | Thyroid function status | p value | ||
|---|---|---|---|---|
| Subclinical hyperthyroidism (n = 77, 2.5%) |
Euthyroidism (n = 3,069, 94.0%) |
Subclinical hypothyroidism (n = 111, 3.5%) |
||
| Abdominal obesitya (%) | 37.7 | 29.1 | 35.1 | 0.206 |
| Hypertensionb (%) | 29.2 | 32.2 | 34.6 | 0.815 |
| Low HDL cholesterolc (%) | 47.0 | 29.7 | 40.0 | 0.003 |
| Elevated triglyceridesd (%) | 30.0 | 30.6 | 35.9 | 0.578 |
| Hyperglycemiae (%) | 27.9 | 30.1 | 30.7 | 0.928 |
| eGFR (mL/min/1.73 m2) | 101.21 (2.13) | 97.90 (0.35) | 95.61 (1.49) | 0.107 |
| eGFR < 60 mL/min/1.73 m2 (%) | 1.5 | 1.5 | 1.5 | 0.999 |
| ACR (mg/g) | 5.92 (0.68) | 15.66 (2.17) | 11.16 (1.80) | < 0.001 |
| ACR ≥ 30 mg/g (%) | NA | 5.8 | 11.1 | 0.020 |
| CKDf (%) | 1.5 | 6.6 | 12.6 | 0.012 |
MetS, metabolic syndrome; HDL, high-density lipoprotein; BP, blood pressure; eGFR, estimated glomerular filtration rate; ACR, albumin-creatinine ratio; CKD, chronic kidney disease
aWaist circumference ≥ 90 cm in men and ≥ 80 cm in women; bBlood pressure ≥ 130/85 mmHg or antihypertensive medication; cHDL cholesterol < 40 mg/dL in men and < 50 mg/dL in women; dTriglycerides ≥ 150 mg/dL; eFasting glucose ≥ 100 mg/dL, glycated hemoglobin (HbA1c) ≥ 6.5% or antidiabetic medication; feGFR < 60 mL/min/1.73 m2 or ACR ≥ 30 mg/g.